Off-patent oral solids and complex generics (inhalers, long-acting, peptides) made in USFDA-approved plants and sold into the US, Europe and emerging markets.
Dr Reddy's LaboratoriesDirect supplier · HighListed
Aurobindo PharmaDirect supplier · HighListed
LupinDirect supplier · HighListed
Zydus LifesciencesDirect supplier · HighListed
CiplaDirect supplier · HighListed
Sun Pharmaceutical IndustriesDirect supplier · MediumListed
Branded formulations (India derma/respiratory, Europe, emerging markets), US generics and the Ichnos Glenmark Innovation (IGI) biotech arm
Price
₹2,299
snapshot 30 Oct 2026
Strengths
IGI licensed trispecific antibody ISB 2001 to AbbVie for US$700m upfront plus up to US$1.225bn milestones and royalties (Sep 2025) - the biggest Indian out-licensing deal
Ryaltris (nasal spray) is a growing global specialty brand
Debt reduced after selling Glenmark Life Sciences (API) to Nirma
Risks
FY26 profit is inflated by the one-off AbbVie upfront - FY27 comparisons will be tough
Repeated USFDA compliance setbacks at several plants have held back US launches
Innovation spend remains high relative to the base business
Note: FY24 loss reflects discontinued operations and one-off charges around the Glenmark Life Sciences sale; FY26 includes the US$700m AbbVie upfront for ISB 2001
Market cap, ratios, CAGR and revenue: company table snapshot as of 30 Oct 2026 (the same figures on every page). Price: snapshot as of 30 Oct 2026. Not investment advice.
Where it fits
Files ANDAs, challenges patents (Para IV) and manufactures generic tablets, capsules and complex dosage forms at scale in USFDA-inspected plants, selling to US wholesalers and pharmacy chains and to European and emerging-market buyers.
Why it matters
India supplies roughly four in ten generic prescriptions filled in the US, and the US is about a third of India's ~US$30bn pharma exports. US generics earnings drive sentiment for the large caps - and are now exposed to two shocks at once: the gRevlimid exclusivity tail ended in Jan 2026, and the US has set a generic-tariff timeline (0% to Jul 2028, 100% then 200%) for companies that do not build US capacity.
Where the value pool sits
Plain oral-solid generics face 5-10% annual US price erosion and are low-margin; profit concentrates in limited-competition products - first-to-file 180-day exclusivities, complex generics (inhalers, injectables, peptides like gLiraglutide/gSemaglutide) and drug-shortage opportunities. When one big product ages out (gRevlimid, gSpiriva, gMyrbetriq), earnings can drop sharply.
Key drivers
Complex-generic and first-to-file launch pipeline
US drug shortages favouring reliable Indian suppliers
GLP-1 / semaglutide patent expiries in Canada, Brazil, India and other markets from 2026
Emerging-market and European expansion to diversify from the US
Potential bottlenecks
USFDA facility status gates approvals: an OAI or warning letter freezes new launches from that plant
Consolidated US buyers (three purchasing groups buy most generics) hold pricing power
Complex generics need device, clinical-endpoint and bioequivalence capabilities few companies have
Investor metrics to watch
US revenue (US$m) per quarter and growth ex-big-product
Number of pending ANDAs / first-to-file opportunities
USFDA status of key sites (VAI / OAI / WL / import alert)